Evolus (EOLS) Projected to Release Earnings on Wednesday

Evolus (NASDAQ:EOLS) is anticipated to post its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $77.58 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Evolus Trading Up 2.8%

Shares of NASDAQ:EOLS opened at $7.37 on Wednesday. The company has a 50-day moving average price of $8.03 and a two-hundred day moving average price of $6.23. Evolus has a twelve month low of $3.86 and a twelve month high of $9.31.

Insider Buying and Selling at Evolus

In other Evolus news, insider David Moatazedi sold 105,108 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $9.04, for a total value of $950,176.32. Following the sale, the insider owned 499,592 shares of the company’s stock, valued at $4,516,311.68. This trade represents a 17.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 5.00% of the company’s stock.

Analyst Ratings Changes

EOLS has been the subject of several research analyst reports. HC Wainwright reissued a “buy” rating and set a $13.00 price objective on shares of Evolus in a research note on Tuesday, August 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evolus in a report on Friday, September 11th. Finally, Wall Street Zen upgraded Evolus from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $14.50.

Evolus Company Profile

Evolus, Inc is a commercial-stage medical aesthetics company focused on developing and marketing products for physicians and other licensed aesthetic providers. The company’s business is centered on minimally invasive treatments intended to address facial lines, wrinkles and other visible signs of aging.

Evolus’ primary product is Jeuveau (prabotulinumtoxinA-xvfs), an injectable botulinum toxin approved by the U.S. Food and Drug Administration for the temporary improvement of moderate to severe glabellar lines, commonly known as “frown lines,” in adults.